EXOSOME-BASED LIQUID BIOPSY
Craif is a pioneer in exosome-based liquid biopsy for accurate and unpainful early cancer detection.
We aim to create a society where everyone can stay healthy throughout their lifetime.
The Number of Medical Institution Installing miSignal®️ Achieved 300
Craif Announced New Product in miSignal®️ Series, “Remote Cancer TestTM”
Craif and Keio University Received Young Investigator Award for a Joint Research on Esophageal Cancer at the 60th Annual Meeting of JSCO
The Number of Medical Institution Installing miSignal®️ Achieved 200
Enrichment of exosomes from body fluid efficiently with a simple procedure allows a more accurate interpretation of cellular communications
miSignal ® is a screening test to determine your risk of developing cancers. It determines cancer risk by utilizing the difference in the expression patterns of microRNAs in the urine of cancer patients and in that of healthy individuals.
